Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ieved to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the exact mechanism of action of Duloxetine is unknown, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and older. Duloxetine is not approved for use in pediatric patients.

Important Safety Information

Duloxetine is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Duloxetine is approved only for adults 18 and over.

Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have including kidney problems, glaucoma, or diabetes. Patients should talk to their doctor if they have itching, right upper belly pain, dark urine, yellow skin or eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been repor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... SOUTH SAN FRANCISCO, Calif. , May 28, 2015 ... the treatment of cancer, today announced that Sean ... at the upcoming Jefferies 2015 Global Healthcare Conference ... 2:30 p.m. EDT on Tuesday, June 2, 2015. Dr. ... including the company,s Precision cancer immunotherapy and Probody drug ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... FRANCISCO, July 21, 2011 ClinStar, LLC , ... and Eastern Europe to the pharmaceutical and biotechnology industry, ... speak at Marcus Evans 6th Annual Clinical Research ... FL.    (Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO ) ...
... July 21, 2011 Endologix, Inc. (NASDAQ: ELGX ... today announced financial results for the three and six months ... and Chief Executive Officer, said, "We are pleased with our ... our growth and new product development goals for 2011.  In ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
(Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Three years ago, ... location for his Shore Vascular & Vein Center! ... circulatory system. It is his mission to provide the ... respect. , Dr. Jeffrey Gosin is Board Certified ... the University of Pennsylvania and Jefferson Medical College. He completed ...
(Date:5/28/2015)... Are policies that spell out when Medicare pays for ... for seniors? That’s what a study published this month ... figure out, and its findings could have implications due ... “Observation Encounters and Subsequent Nursing Facility Stays,” led ... policies that distinguish between an “inpatient” hospital stay and ...
(Date:5/28/2015)... 28, 2015 The Paw Project, ... a dramatic billboard intended to educate the Oregon public ... the busy intersection of Market Street and Park Avenue ... “If You’re for De-clawing Cats, Raise Your Hand,” depicts ... last joint, providing a graphic and anatomically-correct representation of ...
(Date:5/28/2015)... " Trends Investing ” was featured on NewsWatch ... look at small, medium, and large businesses making an impact ... business expert, conducted the business review and shared with viewers ... should invest their money. , The idea, “let your money ... it and knowing how to succeed are two different things. ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2
... important hormone necessary for statural growth and must be ... to grow normally. In healthy individuals, growth hormone is ... that binds to growth hormone receptors on liver and ... secretion of IGF-1 into the bloodstream., ,Any defect ...
... gathering for National Association of Neonatal Nurses Lead Media ... of preventing occurrence of RSV to premature babies. //, ... to 36 weeks gestation each year in the United ... weak immune systems leave these fragile patients susceptible to ...
... Clinic Molecular Immunologist and his team has found a new ... cancer, inflammation and autoimmune diseases. The new delivery system acts ... Therapeutic virus containing the required genes are transferred into the ... are the immune cells they get attracted towards the cancer ...
... people in the world after South Africa and now threats// ... to a World Economic Survey. ,The surveys message ... business due to AIDS in the next five years.", ... report some impact of the AIDS virus on ...
... Drug Azathioprine, which is used as an immunomodulating drug ... and autoimmune disorders is found to increase the incidence ... O’Donovan and colleagues from London Research Institute in Hertfordshire ... the patient taking the drug and when the skin ...
... of a recent study researchers say that certain chemicals found ... help current and former smokers ward off development of lung ... ,Researchers say their study provides significant insight into the ... the process can be slowed down after exposure has already ...
Cached Medicine News:Health News:Skin cancer linked to usage of Drug Azathioprine in organ transplants 2
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
SHERIDAN PREFORMED™ Endotracheal Tubes are designed to conveniently position the anesthesia circuit out of the surgical field for oral and maxillofacial procedures....
Nasal soft cuffed endotracheal tubes designed and constructed especially for long-term nasal intubations....
... is the next step in the ... is an easy to use, easy ... used as a standard tube, as ... quickly and safely handle intubations of ...
Medicine Products: